Latigo Biotherapeutics

Foresite Capital Buys $2.52M of Latigo Biotherapeutics (LTGO) Stock

by
SEC Form 4 filing showing Foresite Capital Management's purchase of Latigo Biotherapeutics shares

Foresite Capital Management V, LLC, a 10%+ owner of Latigo Biotherapeutics, Inc. (LTGO), disclosed an open-market purchase of 140,000 shares on August 10, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at $18.00 apiece, for a total transaction value of $2,520,000.00. This was a straightforward open-market … Read more

Latigo Biotherapeutics (LTGO) Insider Buys $2.52M in Shares

by
SEC Form 4 filing document showing an insider stock purchase at Latigo Biotherapeutics

A newly filed Form 4 shows James B. Tananbaum, an insider at Latigo Biotherapeutics, Inc. (LTGO), purchased 140,000 shares of the company on the open market on August 10, 2026. The transaction was executed at $18.00 per share, for a total outlay of $2,520,000.00 out of the insider’s own funds. Unlike option exercises or grants … Read more